Stifel Nicolaus analyst Rick Wise maintained a Buy rating on GE Healthcare Technologies Inc yesterday and set a price target of $90.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rick Wise’s rating is based on several promising developments at GE Healthcare Technologies Inc. Firstly, the company has shown an improved hospital capital environment across key regions such as the US, EMEA, and China, which is a positive sign for future growth. Additionally, GEHC management has expressed confidence in accelerating growth for 2026, supported by strong business momentum from recent product innovations like Flyrcado and new ultrasound technologies.
Moreover, there is significant excitement about the ongoing “innovation renaissance” at GEHC, which is expected to drive faster growth in 2027 and beyond. The company’s strategic focus on innovative hardware and software, including the Photonova Spectra photon-counting CT and OMNI Whole Body PET, is anticipated to positively impact order growth. These factors, combined with the company’s robust R&D investments, suggest a favorable outlook for GEHC’s growth trajectory, justifying the Buy rating.
In another report released on December 2, BTIG also maintained a Buy rating on the stock with a $87.00 price target.